Lovastatin, 98%
Element SearchElement SearchStructure SearchStructure Search
Thermo Scientific Chemicals
Lovastatin, 98%
Lovastatin, CAS # 75330-75-5, is a cholesterol lowering compound and inhibitor of HMG-CoA reductase, a rate limiting enzyme in cholesterol synthesis.
Technical SupportCustomer Service
Change viewbuttonViewtableView
Quantity:
100 g
5 g
25 g
ChemDexTry the chem dexTM web app
Catalog number 458831000
Price (JPY)/ Each
-
Request A Quote
Quantity:
100 g
Request bulk or custom format
Chemical Identifiers
CAS75330-75-5
IUPAC Name(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
Molecular FormulaC24H36O5
InChI KeyPCZOHLXUXFIOCF-BXMDZJJMSA-N
SMILESCC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
View more
SpecificationsSpecification SheetSpecification Sheet
Appearance (Color)White to light yellow
Appearance (Form)Powder
Infrared spectrumConforms
HPLC>=97.5 %
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

Applications

• It blocks product ion of mevalonate, a critical compound in the production of cholesterol and isoprenoids

• It can increase cellular resistance to anticancer agents such as doxorubicin • It can induce apoptosis in myeloma cells

• It can cause cell cycle arrest in G1 and G2/M phase

• It also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF

RUO – Research Use Only

General References:

  1. Tobert, A.J. Efficacy and long-term adverse effect pattern of lovastatin. The American Journal of Cardiology. 1988, 62, (15),J28-J34.
  2. Jones, P. MD; Kafonek, S. MD; Laurora, I. PharmD; Donald Hunninghake MD. Comparative Dose Efficacy Study of Atorvastatin VersusSimvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study). The American Journal of Cardiology. 1998, 81, (5),582-587.